Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARS Pharmaceuticals Inc SPRY

Healthcare Biotechnology
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and... see more

Recent & Breaking News (NDAQ:SPRY)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 21, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 21, 2021

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

Business Wire December 17, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 16, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 15, 2021

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire December 14, 2021

Silverback Shareholder Alert

Newsfile December 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

PR Newswire December 13, 2021

Silverback Deadline Alert

Newsfile December 13, 2021

Silverback Update

Newsfile December 12, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline - SBTX

Newsfile December 11, 2021

Silverback Class Action Reminder

Newsfile December 9, 2021

Silverback Shareholder Notice

Newsfile December 8, 2021

Silverback Shareholder Alert

Newsfile December 7, 2021

UPCOMING DEADLINE: Silverback Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile December 7, 2021

Silverback Deadline Alert

Newsfile December 6, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 - SBTX

PR Newswire December 6, 2021

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important January 4 Deadline in Securities Class Action - SBTX

PR Newswire December 5, 2021

SBTX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 4, 2022 in the Class Action Filed on Behalf of Silverback Therapeutics, Inc. Limited Shareholders

Newsfile December 5, 2021

Silverback Update

Newsfile December 5, 2021